{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:43Z","timestamp":1794047443016,"version":"4.8.0"},"reference-count":35,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA) and GPRC5D bispecific antibodies (bsAb) in relapsed\/refractory multiple myeloma (RRMM). The aim of our multi-institutional study was to characterize the incidence, etiologies, and risk factors of infections from the start of therapy to the last follow-up or 90 days after study exit. A total of 66 patients received BCMA bsAb monotherapy, 15 GPRC5D bsAb monotherapy, and 15 GPRC5D bsAb combination therapy with daratumumab and\/or pomalidomide. While the infection rate per 100 days was 0.57 for BCMA bsAb, it was 0.62 for GPRC5D bsAb combination and 0.13 for GPRC5D bsAb monotherapy; P=0.05. The proportion of infections that were grade \u22653 was higher in the BCMA bsAb group compared to the GPRC5D groups (58% vs. 36%; P=0.04). Grade 5 events were observed in 8% (n=8) of the patients, all treated with BCMA bsAb. The 9 month cumulative incidence of any grade of infection was similar in the BCMA and GPRC5D-combination groups (57% and 62%) and significantly higher than in the GPRC5D-mono group (16%); P=0.012. The cumulative incidence of grade \u22653 infections was highest in the BCMA group reaching 54% at 18 months; P=0.06. Multivariate analysis showed that BCMA bsAb therapy or GPRC5D combination therapy, history of previous infections, baseline lymphopenia, and baseline hypogammaglobulinemia were significantly associated with a higher risk of grade \u22653 infections. Our results indicate that BCMA bsAb and GPRC5D-combination therapies in RRMM are associated with higher cumulative incidence of infection and grade \u22653 infection compared to GPRC5D bsAb mono.<\/jats:p>","DOI":"10.3324\/haematol.2023.283590","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:12:38Z","timestamp":1693411958000},"page":"906-914","source":"Crossref","is-referenced-by-count":63,"title":["The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Lindsay","family":"Hammons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniko","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Janardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanka","family":"Annyapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Al Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabarinath Venniyil","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Narra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divaya","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilan","family":"Thanendrarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Janz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos Rico","family":"Crescencio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"58751","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"58752","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"58753","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01504"},{"key":"58754","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"58755","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"58756","doi-asserted-by":"crossref","unstructured":"Mailankody S, Devlin SM, Landa J. GPRC5D-targeted CAR T cells for myeloma. N Engl J Med. 2022; 387(13):1196-1206.","DOI":"10.1056\/NEJMoa2209900"},{"key":"58757","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547"},{"key":"58758","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159009"},{"key":"58759","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"58760","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159969"},{"key":"58761","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"58762","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988"},{"key":"58763","doi-asserted-by":"crossref","unstructured":"Mohan M, Nagavally S, Dhakal B. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022; 6(8):2466-2470.","DOI":"10.1182\/bloodadvances.2021006178"},{"key":"58764","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01506-9"},{"key":"58765","doi-asserted-by":"crossref","unstructured":"Johnsrud AJ, Johnsrud JJ, Susanibar SA. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019; 185(1):187-189.","DOI":"10.1111\/bjh.15433"},{"key":"58766","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006178"},{"key":"58767","doi-asserted-by":"crossref","unstructured":"Hammons LR, Szabo A, Janardan A. Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma. JAMA Netw Open. 2022; 5(10):e2238961.","DOI":"10.1001\/jamanetworkopen.2022.38961"},{"key":"58768","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.010"},{"key":"58769","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.38961"},{"key":"58770","unstructured":"Department of Health and Human Services US. Common Terminology Criteria for Adverse Events (CTCAE). 2017."},{"key":"58771","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"58772","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"58773","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"58774","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211035272"},{"key":"58775","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15433"},{"key":"58776","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956"},{"key":"58777","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100810"},{"key":"58778","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"58779","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8"},{"key":"58780","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711"},{"key":"58781","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004079"},{"key":"58782","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"58783","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148223"},{"key":"58784","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909"},{"key":"58785","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283590\/76026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283590\/76683","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11247\/76026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:43Z","timestamp":1794045883000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283590","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}